Navigation Links
PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
Date:9/1/2009

ANNAPOLIS, Md., Sept. 1 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that management will present at the Rodman & Renshaw Annual Global Investment Conference 2009. The Company is scheduled to present on Thursday, September 10th, 2009 at 10:00 a.m. E.T. in the Hubbard Salon (5th Floor) at the New York Palace Hotel, New York. The presentation will be webcast and can be accessed at http://www.wsw.com/webcast/rrshq15/pip.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) -- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) -- a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit www.PharmAthene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
2. PharmAthene to Host Second Quarter 2009 Conference Call and Webcast on Thursday, August 13, 2009
3. PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
4. PharmAthenes 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review
5. PharmAthene Reports First Quarter 2009 Financial and Operational Results
6. PharmAthene Announces New Date for First Quarter 2009 Conference Call and Webcast
7. PharmAthene to Host First Quarter 2009 Conference Call and Webcast on Thursday, May 14, 2009
8. PharmAthene Presents Data for SparVax(TM), a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research
9. PharmAthene Announces $5.5 Million Public Equity Offering
10. PharmAthene To Host Year-End 2008 Earnings Conference Call and Webcast on Monday, March 30, 2009
11. PharmAthene Presents Data for SparVax(TM) and Valortim(R), a Novel Vaccine and Anti-Toxin for the Prevention and Treatment of Anthrax Infection at the 7th Annual ASM Biodefense Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/2/2019)... YORK (PRWEB) , ... October 31, 2019 , ... ... been released by pharma artificial intelligence pioneer tellic. drug360 brings tellic’s expertise ... This new tool allows researchers to quickly uncover relationships between genes, diseases, variants, ...
(Date:10/29/2019)... Conn. (PRWEB) , ... October 28, 2019 , ... ... Advisory Board: , , Professor Jack R Wands, MD, of ... and Wyeth (Pfizer) , Professor Gil Mor, MD, PhD, of Wayne State ...
(Date:10/26/2019)... ... , ... Sparks Marketing Group, Inc. (Sparks) announced ... healthcare-specific marketing firm, to strengthen the agency’s growing focus on the healthcare vertical ... in pharma, bio-therapeutics, medical device and healthcare technologies currently account for a large ...
(Date:10/22/2019)... ... 22, 2019 , ... Enplug , a leading cloud-based ... into its digital signage platform. The collaboration brings one of the most trusted ... to leverage their existing digital signage networks to quickly disseminate critical safety information ...
Breaking Biology Technology:
(Date:11/12/2019)... ... November 12, 2019 , ... In’Tech Medical SAS ( ... the creation of a Global Regulatory Affairs Department, to support Medical Device companies ... the regulatory element to any Medtech organization is more important than Research & ...
(Date:11/12/2019)... ... November 12, 2019 , ... The Arnold and Mabel ... and research institutions for its Instrumentation Grant for Advanced Light-Sheet Microscopy and ... per site for the acquisition of instrumentation, development and maintenance; support for data ...
(Date:11/9/2019)... , ... November 08, 2019 , ... SiteSeer Technologies, creator ... as a new client and user of SiteSeer. The boutique real estate developer ... the U.S. will use SiteSeer to supplement its own analysis of markets. , ...
Breaking Biology News(10 mins):